BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 26053357)

  • 21. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
    Cerva C; Maffongelli G; Svicher V; Salpini R; Colagrossi L; Battisti A; Mariotti B; Cerretti R; Cudillo L; Sarmati L
    BMC Infect Dis; 2017 Aug; 17(1):566. PubMed ID: 28806922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
    Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.
    Seto WK; Wong DK; Chan TS; Hwang YY; Fung J; Liu KS; Gill H; Lam YF; Cheung KS; Lie AK; Lai CL; Kwong YL; Yuen MF
    Am J Gastroenterol; 2016 Dec; 111(12):1788-1795. PubMed ID: 27644733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.
    Uhm JE; Kim K; Lim TK; Park BB; Park S; Hong YS; Lee SC; Hwang IG; Koh KC; Lee MH; Ahn JS; Kim WS; Jung CW; Kang WK
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):463-8. PubMed ID: 17382252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy.
    Lee JY; Lim SH; Lee MY; Kim H; Sinn DH; Gwak GY; Choi MS; Lee JH; Jung CW; Jang JH; Kim WS; Kim SJ; Kim K
    Liver Int; 2015 Nov; 35(11):2363-9. PubMed ID: 25832927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
    Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
    Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
    Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
    Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
    Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
    J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation.
    Gärtner BC; Jung W; Welsch C; Fischinger J; Schubert J; Zeuzem S; Mueller-Lantzsch N; Wend UC; Gerlich WH
    J Clin Virol; 2007 Feb; 38(2):146-8. PubMed ID: 17182277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
    Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.